Four-week course efficacious and safe for treatment-resistant depression
Mean change in Preclinical Alzheimer Cognitive Composite score not significantly different at 240 weeks with solanezumab, placebo
Implementation of training session increased proportion of patients with documented Abnormal Involuntary Movement Score
Slows clinical progression at 76 weeks for those with low/medium tau and the combined low/medium and high tau pathology population
Three case reports from Iceland spurred the review; two of the cases involved Ozempic
No evidence seen for link between childhood stimulant treatment and substance use during adolescence and young adulthood
For first three approved indications, second and third indication approvals less likely to have high value rating
No impact on receipt of opioid or nonopioid pain treatment seen among patients with chronic noncancer pain
Strongest demographic predictor for discharge initiation of medications for alcohol use disorder was younger age
No significant difference in verified seven-day abstinence seen by treatment group among Black adults who smoke daily